Search:

Research

My research interests center on understanding how inflammatory mediators contribute to age-related neurodegenerative disease and multiple sclerosis.

Our work has concentrated on how the enzyme Cyclooxygenase-2 (COX-2) contributes to injury of neurons and oligodendrocytes. An understanding of how COX-2 contributes to the pathophysiology of neurodegenerative diseases could lead to new therapeutic approaches to preventing or treating diseases of the central nervous system.

Selected Publications

Search Pubmed for Noel Carlson's lab publications

• Carlson NG, Rojas MA, Redd JW, Tang P, Wood B, Hill KE, Rose JW. 2010.  Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death.  J Neuroinflammation 7:25
• Greenlee JE, Clawson SA, Hill KE, Dechet CB, Carlson NG.  2010.  Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate.  J Neurol Sci. 291(1-2):74-78. Epub 2010 Jan 20.
• Hill KE, Clawson SA, Rose JW, Carlson NG, Greenlee JE. 2009.  Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics. J. Neuroinflammation 6:31.
• Rojas M.R., Carlson N.G., Miller T.L. and Rose J.W.  2009. Long Term Daclizumab Therapy in Relapsing Remitting Multiple Sclerosis.  Therapeutic Advances in Neurological Disorder.  2(5):291-297.
• Carlson N.G., Rojas M.R., Black J.D, Redd J.W., Hill K.E., Hille J., Rose J.W.  2009.  Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor.  J. Neuroinflammation 6:5.
• Zhang Y, Nelson R. D., Carlson N G., Kamerath C D, Kohan D E, Kishore B K. 2009.  Potential Role of Purinergic Signaling in Lithium-induced Nephrogenic Diabetes Insipidus Am J Physiol Renal Physiol, 296(5):F1194-201.]
• Kishore B. K., Nelson R. D., Miller R. L, Carlson N G. and Kohan D. E.. 2009. P2Y2 Receptor and Water Transport in the Kidney.  Invited Review for Purinergic Signaling 5(4):491-9.
• Rose J.W., Foley J. and Carlson N.G. 2008.  Monoclonal Antibodies for Treatment of Multiple Sclerosis” Current Neurology and Neuroscience Reports 8(5):419-426.
• Rose J., Burns, J.B. Bjorklund J., Klein J., Watt H., and Carlson N. G. 2007. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69:785-789.
• Rose J. W. and Carlson N.G. 2007. Pathogenesis of Multiple Sclerosis. Continuum Lifelong Learning Neurol.13(5):35-62.
• Tsoi V.L., Hill, K.E., Carlson N.G., Rose J.W. 2006. Evidence for Inducible Nitric Oxide Synthase and Peroxynitrite Mediated Damage in Optic Neuritis. Journal of Neuro-Ophthalmology 26:87-94.
• Carlson N.G. and J.W. Rose. 2006. Antioxidants in multiple sclerosis: Do they have a role? CNS Drugs 20(6):433-441.
• Carlson N.G., K.E. Hill, I Tsunoda, R.S. Fujinami, J.W. Rose. 2006. The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: Implications for multiple sclerosis. Journal of Neuroimmunology 174(1-2):21-31.
• Carlson N.G. and J.W. Rose. 2006. Antioxidants in multiple sclerosis: Do they have a role? CNS Drugs 20(6):433-441.
• Rose, J.W., K.E. Hill, H. Watt and N.G. Carlson. 2004. Inflammatory Cell Expression of Cyclooxygenase-2 (COX-2) in the MS Lesion. Journal of Neuroimmunology 149:40-49.
• Carlson N.G., 2003. Neuroprotection mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. Journal of Neurosci. Res 71:79-88.